Shunsuke Tatsuki
0283695, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Benefits of PARP inhibitor rechallenge in patients with platinum-sensitive recurrent ovarian cancer previously treated with a PARP inhibitor: a multicenter retrospective study.
Journal: International journal of clinical oncology
Published: January 16, 2026
Efficacy and safety of bevacizumab-combined single-agent chemotherapy for platinum-resistant ovarian cancer that recurred during PARP inhibitor treatment.
Journal: International journal of clinical oncology
Published: October 20, 2025
Efficacy of Platinum-based Chemotherapy for Platinum-sensitive Recurrent Ovarian Cancer During PARP Inhibitor Treatment: A Multicenter Retrospective Study.
Journal: Anticancer research
Published: September 20, 2025
Treatment strategies for advanced and recurrent endometrial cancer using immune checkpoint inhibitors.
Journal: International journal of clinical oncology
Published: August 02, 2024
Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer.
Journal: Cancers
Published: June 05, 2024
Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study.
Journal: Anticancer research
Published: June 14, 2022
Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas.
Journal: Cancers
Published: October 29, 2021
Comparison of Postoperative Adjuvant Chemotherapy and Concurrent Chemoradiotherapy for FIGO2018 Stage IIIC1 Cervical Cancer: A Retrospective Study.
Journal: Medicina (Kaunas, Lithuania)
Published: April 19, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026